Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$23,500.00

Synthesis of N-(4-oxo-1-adamantyl)acetamide

EF 2011-12

Résumé
BioMark is a Canadian based medical technology company that is focused on the research, development and commercialization of its novel Acetylated Biomarker Assay (ABA) Red Alert technology. BioMark's novel technology works by following a particular the enzyme, spermine/spermidine N-acetyltransferase (SSAT), that is up-regulated in solid tumours. Following the over-expressed enzyme of tumours by the detection system is the basis of determining tumour burden. Despite this important breakthrough, testing remains quite expensive. To make the tests more cost effective, BioMark intends to develop an in vitro diagnostic kit using monoclonal antibodies. BioMark has discovered that that the adjuvent of a small molecule (AA) binds to a specific antibody (Ab) that does not bind to that of the native ligand. BioMark has a rabbit mode that contains circulating B cells that secrete this particular Ab. BioMark intends to establish a better antibody with higher frequency that is specific to the AA. To do so, gram quantities of AA are needed. This compound is commercially available via custom synthesis, but is prohibitively expensive. A synthetic route has been published, but is highly inefficient and is not readily scalable. Moreover, the literature report does not provide an experimental procedure, which severely limits reproducibility. The goal of this project is to develop an efficient synthetic route to AA. We propose a more concise synthetic pathway, based on a more recent report than the known synthesis. The proposed route is expected to be highly scalable. This will allow the synthesis of sufficient quantities for biological testing/immunizing the rabbits to help boost production of the required antibodies.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
416358-2011
Name nom
Love, Jennifer
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
23500
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Synthesis of N-(4-oxo-1-adamantyl)acetamide
Keyword
NSERC
Application summary
BioMark is a Canadian based medical technology company that is focused on the research, development and commercialization of its novel Acetylated Biomarker Assay (ABA) Red Alert technology. BioMark's novel technology works by following a particular the enzyme, spermine/spermidine N-acetyltransferase (SSAT), that is up-regulated in solid tumours. Following the over-expressed enzyme of tumours by the detection system is the basis of determining tumour burden. Despite this important breakthrough, testing remains quite expensive. To make the tests more cost effective, BioMark intends to develop an in vitro diagnostic kit using monoclonal antibodies. BioMark has discovered that that the adjuvent of a small molecule (AA) binds to a specific antibody (Ab) that does not bind to that of the native ligand. BioMark has a rabbit mode that contains circulating B cells that secrete this particular Ab. BioMark intends to establish a better antibody with higher frequency that is specific to the AA. To do so, gram quantities of AA are needed. This compound is commercially available via custom synthesis, but is prohibitively expensive. A synthetic route has been published, but is highly inefficient and is not readily scalable. Moreover, the literature report does not provide an experimental procedure, which severely limits reproducibility. The goal of this project is to develop an efficient synthetic route to AA. We propose a more concise synthetic pathway, based on a more recent report than the known synthesis. The proposed route is expected to be highly scalable. This will allow the synthesis of sufficient quantities for biological testing/immunizing the rabbits to help boost production of the required antibodies.